ORIEN Member Presentations at 2023 ASCO Demonstrate Unique Value of Aster Insights’ Data

Aster Insights has announced its participation as a research partner at the American Society of Clinical Oncology (ASCO) Annual Meeting June 2-6, 2023, in Chicago. An oral presentation and three posters will be presented at this year’s ASCO meeting, utilizing the lifetime patient-consented longitudinal clinicogenomic data from the company’s Oncology Research Information Exchange Network® (ORIEN) AVATAR program. These presentations highlight the research partnerships and collaboration of Aster Insights and 18 premier cancer centers that comprise ORIEN.

“We are thrilled to be selected for these diverse presentations at ASCO that showcase the incredible work of ORIEN and Aster Insights,” said Jill Kolesar, PharmD, director of the Precision Medicine Center at the Markey Cancer Center and chair of the ORIEN Executive Advisory Committee. “The partnership in research and broad national collaboration that define our work help drive critical breakthroughs in discovery and the development of next-generation treatments for cancer patients.”

The research projects focus on cancer immunotherapy, risk reduction, and reporting inherited cancer risks. Partnering with ORIEN members, Aster Insights enables critical scientific intelligence and insights to advance patient care by providing the richest real-world dataset in oncology, comprised of whole exome sequencing (WES), while transcriptome sequencing (WTS), germline data, and lifetime clinical patient data.

ORIEN’s presentations will take place on June 3, 2023. They are as follows:

  • Molecular Basis for Young-Onset Colorectal Cancer Clinical Science Symposium: Deepak Vadehra, DO, from Roswell Park Comprehensive Cancer Center will deliver an oral presentation titled “Transcriptional metabolic profiling in young onset colorectal cancer (CRC) patients. The full symposium offers 1.5 CE credits, and Dr. Vadehra’s talk will take place from 4:30 to 4:42 p.m. in Hall D2.
  • Developmental Therapeutics—Immunotherapy Poster Session: Xuefeng Wang, PhD, from Moffitt Cancer Center will present a poster session titled “Incorporating long non-coding RNA (lncRNA) into genome-wide biomarker screening for prognostic gene signatures of immunotherapy outcomes” from 9 a.m. to noon in Hall A.
  • Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Poster Session: Timothy Shaw, PhD, from Moffitt Cancer Center will present a poster session titled “Genetic heterogeneity between paired primary and metastatic solid tumors and implications for neoantigen-based personalized cancer vaccines” from 9 a.m. to noon in Hall A.
  • Prevention, Risk Reduction, and Hereditary Cancer Poster Session: Megan Hutchcraft from the University of Kentucky Markey Cancer Center, will deliver a poster session titled “Clinical utility of reporting research genetic predisposition testing results to Total Cancer Care participants” from 2:15 to 5:15 p.m. in Hall A.

Aster Insights representatives will have a booth (#23174) at the ASCO conference and invite ASCO attendees, oncology colleagues, and research partners to meet with them at any time during the conference.

Read the original press release here.